Persistent Fracture Reduction with Abaloparatide-SC (TYMLOS ™) Followed by 24 Months of Alendronate

In the ACTIVE phase III trial, 2463 postmenopausal women with osteoporosis were randomized 1:1:1 to abaloparatide (ABL; n=824), blinded placebo (PBO; n=821), or open-label teriparatide (n=818). During ACTIVE, ABL increased BMD and reduced vertebral, nonvertebral, clinical, and major osteoporotic fractures compared to PBO. Women who completed ABL or PBO treatment in ACTIVE were eligible to enroll in an extension study (ACTIVExtend) to receive up to 24 months of open-label alendronate (ALN).

Source: Journal of Clinical Densitometry - October 1, 2018 Category: Radiology Authors: K.G. Saag, P.D. Miller, F. Cosman, LA Fitzpatrick, G Hattersley, B Mitlak, JP Bilezikian, RK Dore Source Type: research